Shares in Medicover AB, the Swedish-headquartered healthcare and diagnostics group, surged on Wednesday after the company reported second-quarter results that exceeded market expectations and upgraded its full-year financial targets. The stock rose by 6.2% in midday trading on the Stockholm Stock Exchange, reaching a fresh 12-month high, as investors welcomed the improved outlook.
For the three months ended 30 June 2026, Medicover posted revenue of €685 million, up 11% year-on-year, while adjusted earnings before interest and taxes (EBIT) came in at €72 million, ahead of the consensus forecast of €64 million. The company attributed the outperformance to higher patient volumes across its hospital network in Poland, Germany, and India, as well as continued growth in its diagnostic laboratory services division.
In a statement, Medicover’s chief executive said the group now expects full-year revenue growth of at least 10% (previously 8-9%) and an EBIT margin of around 10.5%, up from earlier guidance of 9.5-10%. The upgrade reflects both operational efficiencies and a favourable demand environment for private healthcare services across Central and Eastern Europe.
Analysts at Kepler Cheuvreux raised their price target on the stock from €175 to €195, citing “strong organic momentum and a clear path to margin expansion”. They noted that Medicover’s integrated care model, which combines hospitals, clinics, and labs, continues to attract both insured and self-pay patients in markets where public healthcare systems face capacity constraints.
For UK investors, the move is relevant primarily through exposure in European healthcare funds or exchange-traded funds (ETFs) that hold Medicover shares. While the company is not listed in London, its performance can influence sentiment in the broader healthcare sector, particularly among peers such as Spire Healthcare and Ramsay Générale de Santé. The FTSE 100 edged up 0.3% on the day, with healthcare stocks providing a modest tailwind.